NCT01455571View on ClinicalTrials.gov

Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Advanced Solid Tumor
Interventions
DRUG

HM781-36B

Q1DX14/2W for 3W HM781-36B

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Seoul National University

OTHER

lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT01455571 - Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter